H.U. Group’s consolidated financial results for the fiscal year ending March 2026 show revenue of \u00a52,473.362 billion (an increase of 1.8%) and net income attributable to shareholders of \u00a56.823 billion (a rise of 147.1%). Segments such as testing and related services performed steadily, with operating profit expanding to \u00a54.78 billion. The planned dividend for the period is \u00a5125 per share.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4544","jir_company_name":"H.U. Group Holdings, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4544-20260514-01.pdf","jir_short_summary":"H.U. Group's consolidated financial results for the fiscal year ending March 2026 show revenue of \u00a52,473.362 billion (an increase of 1.8%) and net income attributable to shareholders of \u00a56.823 billion (a rise of 147.1%). Segments such as testing and related services performed steadily, with operating profit expanding to \u00a54.78 billion. The planned dividend for the period is \u00a5125 per share.","jir_summary":"### Performance Overview\nH.U. Group achieved revenue of \u00a52,473.362 billion (an increase of 1.8%), operating profit of \u00a54.78 billion (an increase of 81.0%), and net income attributable to shareholders of \u00a56.823 billion (an increase of 147.1%) for the fiscal year ending March 2026. Steady performance was observed in testing and related services segments and clinical diagnostic reagent businesses, especially driven by new blood testing products and FDA approvals in the United States. The planned dividend for the year is \u00a5125 per share, with continual share buyback programs in place. Overall, the company maintains profitability and financial soundness while anticipating future growth.\n\n### Outlook and Shareholder Impact\nFor the fiscal year ending March 2027, the company anticipates revenue of \u00a52,560.0 billion (a 3.5% increase) and net income of \u00a55.0 billion (a 26.7% decrease). The dividend remains at \u00a5125 per share, with ongoing share buyback initiatives. The company intends to sustain a solid financial position with a capital adequacy ratio of 51.3%, promoting growth strategies accordingly.","jir_financial_highlights":"Revenue: \u00a52,473.362 billion (up 1.8% year-over-year)\nNet income attributable to shareholders: \u00a56.823 billion (up 147.1% year-over-year)\nOperating profit: \u00a54.78 billion (up 81.0% year-over-year)","jir_category":"","jir_hashtags":"#HUGP, #FinancialResults, #JapanStocks","jir_key_figures":"Revenue: \u00a52,473.362 billion (up 1.8% YoY)\nNet income attributable to shareholders: \u00a56.823 billion (up 147.1% YoY)\nDividend: \u00a5125 (annual estimate)","jir_meta_title":"\u3010H.U.\u30112026 Financial Results | Revenue of \u00a52.47 trillion, Net Income of \u00a56.8 billion","jir_meta_description":"H.U. Group's financial results for the fiscal year ending March 2026 show revenue of \u00a52,473.362 billion (up 1.8%) and net income of \u00a56.823 billion (up 147.1%). Details on future growth strategies and dividend forecasts are included.","jir_og_title":"\u3010H.U.\u30112026 Financial Results | Revenue of \u00a52.47 trillion, Net Income of \u00a56.8 billion","jir_og_description":"H.U. Group's fiscal year ending March 2026 posted increased revenue and profit. Detailed projections for future growth and dividends are provided.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[243025,247362,\\\"unknown\\\"],\\\"borderColor\\\":\\\"#36A2EB\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Profit Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Profit\\\",\\\"data\\\":[2640,4780,\\\"unknown\\\"],\\\"borderColor\\\":\\\"#FF6384\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Testing & Related Services\\\",\\\"Clinical Diagnostic Reagents\\\",\\\"Healthcare Related Services\\\"],\\\"datasets\\\":[{\\\"data\\\":[157297,60735,29330],\\\"backgroundColor\\\":[\\\"#FF6384\\\",\\\"#36A2EB\\\",\\\"#FFCE56\\\"]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Profit Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Revenue\\\",\\\"Operating Profit\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Ratio\\\",\\\"data\\\":[\\\"unknown\\\",\\\"81.0\\\"],\\\"backgroundColor\\\":\\\"#4BC0C0\\\"}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"2027 Forecast vs. Actual Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Revenue\\\",\\\"Net Income\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Forecast\\\",\\\"data\\\":[256000,5000],\\\"backgroundColor\\\":\\\"#9966FF\\\"},{\\\"label\\\":\\\"Actual\\\",\\\"data\\\":[247362,6823],\\\"backgroundColor\\\":\\\"#FF6384\\\"}]},\\\"options\\\":{}}\"}]","ir_related_company":9022,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-50129","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n